Research programme: chikungunya infections therapeutics- Protinhi Therapeutics
Latest Information Update: 12 Jun 2023
Price :
$50 *
At a glance
- Originator Protinhi Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Viral protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Chikungunya virus infections
Most Recent Events
- 12 Jun 2023 Research programme: chikungunya virus infections - Protinhi Therapeutics is available for licensing as of 12 June 2023. https://www.protinhi.com/rd/
- 30 Nov 2021 Research programme: chikungunya virus infections - Protinhi Therapeutics is available for licensing as of 30 Nov 2021. https://www.protinhi.com/rd/
- 30 Nov 2021 Early research in Chikungunya virus infections in Netherlands (PO) befor November 2021 (Protinhi Therapeutics pipeline, November 2021)